GU Cancers 2019 | JAVELIN: safety and efficacy 2-year follow up
Andrea Apolo, MD, of the National Cancer Institute, Bethesda, MD, presents the latest safety and efficacy analysis from 2-year follow up of the Phase Ib JAVELIN study (NCT01772004), evaluating avelumab treatment for metastatic urothelial carcinoma, at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.
Transcript (edited for clarity)
So this year at GU ASCO 2019, we have a 2.7 year follow-up of the trial of patients receiving Avelumab in the second line setting. These are patients that are refractory to cisplatinum that received
So this year at GU ASCO 2019, we have a 2.7 year follow-up of the trial of patients receiving Avelumab in the second line setting. These are patients that are refractory to cisplatinum that received Avelumab and this was a 250 cohort that led to the FDA approval. So we have long-term follow-up looking at the response rate and the response efficacy. The overall response rate was 16.5% and we saw that this was a prolonged duration. The duration of response was 20.5 months. So that was pretty impressive. And at 12 months, 65% of the patients were still responding. So this confirms the long efficacy of Avelumab in this patient population of metastatic bladder cancer patients that are refractory to standard cisplatinum-based chemotherapy.
Read more...
